Recently, Peng et al. (2022), performing RNA-Seq data analysis in stomach adenocarcinomas, demonstrated that the lncRNA TM4SF1-AS1 inhibits the immune killing capacity mediated by T cells and serves as a prognostic marker for assessing the immune response to anti-PD1 therapy [112]. Here, TM4SF1 is linked to gastric adenocarcinoma.